LGM Pharma API Sourcing. CDMO Services, Regulatory Expertise. LGM Pharma API Sourcing. CDMO Services, Regulatory Expertise.

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of Celerion.

    Client Virtual Booth

    CELERION

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    SERVICES

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Celerion
    United_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    621 Rose Street Lincoln, NE 68502
    Telephone
    Telephone
    +1.402.476.2811
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.celerion.com/
    Linkedin
    Linkedin
    http://www.linkedin.com/company/905785?trk=vsrp_companies_res_name&trkInfo=VSRPsearchId%3A225289961376491208125%2CVSRPtargetId%3A905785%2CVSRPcmpt%3Aprimary
    Twitter
    Twitter
    http://twitter.com/Sci2Medicine

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    left grey arrow
    right gray arrow
    Full View ScreenFull Screen View
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Prometheus Biosciences Commences Dosing in Multiple Ascending Dose (MAD) Portion of Ongoing Phase 1a Clinical Study of PRA023

    Details:

    PRA023, the company's lead product candidate, is a humanized IgG1 monoclonal antibody (mAb) that has been shown to block tumor necrosis factor (TNF)-like ligand 1A (TL1A).


    Lead Product(s): PRA023

    Therapeutic Area: Gastroenterology Product Name: PRA023

    Highest Development Status: Phase IProduct Type: Large molecule

    Recipient: Prometheus Biosciences

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable March 03, 2021

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Neuropore Completes Phase 1 Clinical Trial in Healthy Volunteers with NPT520-34, a Therapeutic Candidate Aimed at Treating Parkinson’s Disease and Amy...

    Details:

    The Phase 1 study was designed to evaluate the safety, tolerability and pharmacokinetics of single and multiple doses of NPT520-34.


    Lead Product(s): NPT520-34

    Therapeutic Area: Neurology Product Name: NPT520-34

    Highest Development Status: Phase IProduct Type: Small molecule

    Recipient: Neuropore Therapies

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable January 13, 2020

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    pfizer-centreone-m-2023-06-05

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search